Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 719 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colitis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Data Bank for Eosinophilic Disorders

NCT00267475
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastritis, Enteritis, Eosinophilic Colitis, Eosinophilic Gastroenteritis
Interventions
Not listed
Lead sponsor
Marc Rothenberg
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 21, 2026, 8:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Urinary Isoprostanes in the Assessment of Children With Inflammatory Bowel Disease

NCT00215020
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 21, 2026, 8:58 PM EDT
Completed No phase listed Observational

Post-Op Quality of Life After Colorectal Surgery

NCT00468455
View directory record Official record
Conditions
Colorectal Neoplasms, Colitis, Ulcerative, Diverticulitis, Colonic Polyps, Crohn Disease
Interventions
Laparoscopic or open colorectal surgery
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 21, 2026, 8:58 PM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Ulcerative Colitis

NCT04148274
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 21, 2026, 8:58 PM EDT
Not listed Phase 1 Interventional

Pilot Study of a New Medical Food in the Management of Ulcerative Colitis

NCT06116643
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Soluble protein hydrolysate (SPHi)
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 21, 2026, 8:58 PM EDT
Recruiting Phase 1 Interventional

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

NCT07665723
View directory record Official record
Conditions
Active Ulcerative Colitis
Interventions
Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 8:58 PM EDT
Not listed Phase 3 Interventional

High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade

NCT03162432
View directory record Official record
Conditions
IBD, Ulcerative Colitis, Crohn Disease
Interventions
Vitamin D3
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 21, 2026, 8:58 PM EDT
Terminated Phase 3 Interventional Results available

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

NCT02118584
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
57
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Results available

Bacteriotherapy in Pediatric Inflammatory Bowel Disease

NCT01757964
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, CD
Interventions
Bacteriotherapy
Biological
Lead sponsor
David Suskind
Other
Eligibility
12 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 8:58 PM EDT
Recruiting Phase 3 Interventional

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 19 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
11
States / cities
San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT00628433
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, HE3286
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 21, 2026, 8:58 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

NCT04130919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tilpisertib, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
23
States / cities
Dothan, Alabama • Lancaster, California • Murrieta, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 21, 2026, 8:58 PM EDT
Recruiting No phase listed Observational

Eosinophilic Gastrointestinal Disorders Registry

NCT05199532
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, Eosinophilic Colitis, Eosinophilic Gastrointestinal Disease
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 25 Years
Enrollment
500 participants
Timeline
2020 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Results available

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

NCT04924114
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MK-6194, MK-6194-matching placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Rialto, California • Kissimmee, Florida • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 21, 2026, 8:58 PM EDT
Terminated No phase listed Observational

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

NCT03802214
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vedolizumab
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 2Phase 3 Interventional

Trial of Mesalamine for the Treatment of Active Microscopic Colitis

NCT00952952
View directory record Official record
Conditions
Microscopic Colitis, Diarrhea
Interventions
Mesalamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

NCT02522767
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
18
States / cities
Little Rock, Arkansas • Murrieta, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 21, 2026, 8:58 PM EDT
Completed No phase listed Observational

Self-Management Assistance for Recommended Treatment (SMART) Portal

NCT01966744
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of Rosiglitazone for Ulcerative Colitis

NCT00065065
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 1 Interventional

A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

NCT01320332
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ASP3291, Placebo
Drug
Lead sponsor
Telsar Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Anaheim, California • Baltimore, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Not applicable Interventional

SMART-IBD App Trial

NCT06023667
View directory record Official record
Conditions
Inflammatory Bowel Diseases, IBD, Crohn Disease, Ulcerative Colitis
Interventions
SMART-IBD
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 21, 2026, 8:58 PM EDT
Active, not recruiting Phase 4 Interventional

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

NCT04835506
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 8:58 PM EDT
Not yet recruiting Phase 1 Interventional

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

NCT05852587
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions
Xylitol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 8:58 PM EDT